186 related articles for article (PubMed ID: 30287313)
1. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review.
Zakhem GA; Motosko CC; Mu EW; Ho RS
J Am Acad Dermatol; 2019 Apr; 80(4):957-969. PubMed ID: 30287313
[TBL] [Abstract][Full Text] [Related]
2. Dermatological medication effects on male fertility.
Millsop JW; Heller MM; Eliason MJ; Murase JE
Dermatol Ther; 2013; 26(4):337-46. PubMed ID: 23914891
[TBL] [Abstract][Full Text] [Related]
3. Review of dermatologic medications and impact on male fertility, sexual dysfunction and teratogenicity.
Hui EX; Huang X; Oon HH
Andrology; 2022 Oct; 10(7):1272-1285. PubMed ID: 35876714
[TBL] [Abstract][Full Text] [Related]
4. Paternal safety of anti-rheumatic medications.
Bermas BL
Best Pract Res Clin Obstet Gynaecol; 2020 Apr; 64():77-84. PubMed ID: 31727565
[TBL] [Abstract][Full Text] [Related]
5. The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review.
Perez-Garcia LF; Dolhain RJEM; Vorstenbosch S; Bramer W; van Puijenbroek E; Hazes JMW; Te Winkel B
Hum Reprod Update; 2020 Nov; 26(6):961-1001. PubMed ID: 32743663
[TBL] [Abstract][Full Text] [Related]
6. Sexual dysfunction in men taking systemic dermatologic medication: A systematic review.
Zakhem GA; Goldberg JE; Motosko CC; Cohen BE; Ho RS
J Am Acad Dermatol; 2019 Jul; 81(1):163-172. PubMed ID: 30905792
[TBL] [Abstract][Full Text] [Related]
7. Comment on "Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review".
Enriquez-Gutierrez G; Sosaya-Muñoz F; Rojas-Varona C; Mezones-Holguín E
J Am Acad Dermatol; 2019 Jun; 80(6):e173-e174. PubMed ID: 30654080
[No Abstract] [Full Text] [Related]
8. Response to: "Comment on 'Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review'".
Zakhem GA; Motosko CC; Mu EW; Ho RS
J Am Acad Dermatol; 2019 Jun; 80(6):e175-e176. PubMed ID: 30654081
[No Abstract] [Full Text] [Related]
9. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence.
Mouyis M; Flint JD; Giles IP
Semin Arthritis Rheum; 2019 Apr; 48(5):911-920. PubMed ID: 30220537
[TBL] [Abstract][Full Text] [Related]
10. The toxicity of methotrexate in male fertility and paternal teratogenicity.
Gutierrez JC; Hwang K
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):51-58. PubMed ID: 27590039
[TBL] [Abstract][Full Text] [Related]
11. The Influence of Methotrexate Treatment on Male Fertility and Pregnancy Outcome After Paternal Exposure.
Grosen A; Kelsen J; Hvas CL; Bellaguarda E; Hanauer SB
Inflamm Bowel Dis; 2017 Apr; 23(4):561-569. PubMed ID: 28267049
[TBL] [Abstract][Full Text] [Related]
12. Depression and acitretin: a true association or a class labeling?
Hayes J; Koo J
J Drugs Dermatol; 2011 Apr; 10(4):409-12. PubMed ID: 21455552
[TBL] [Abstract][Full Text] [Related]
13. Thalidomide, semen distribution, teratogenicity... and cost.
Laffitte E
Br J Dermatol; 2006 Mar; 154(3):563; author reply 563-4. PubMed ID: 16445798
[No Abstract] [Full Text] [Related]
14. Where are the data to assess the safety of paternal drug exposure? A systematic review of secondary databases: A contribution from IMI concePTION.
Gaitonde S; Moride Y; Suarez E; Lopez-Leon S
Pharmacoepidemiol Drug Saf; 2024 Feb; 33(2):e5764. PubMed ID: 38357834
[TBL] [Abstract][Full Text] [Related]
15. Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.
Liu M; Huang YY; Hsu S; Kass JS
CNS Drugs; 2016 Dec; 30(12):1149-1168. PubMed ID: 27832476
[TBL] [Abstract][Full Text] [Related]
16. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease.
Margolis DJ; Fanelli M; Hoffstad O; Lewis JD
Am J Gastroenterol; 2010 Dec; 105(12):2610-6. PubMed ID: 20700115
[TBL] [Abstract][Full Text] [Related]
17. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
Stobaugh DJ; Deepak P; Ehrenpreis ED
J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis May Explain the Pharmacological Mode of Action and Adverse Effects of Isotretinoin, Including Teratogenicity.
Melnik BC
Acta Derm Venereol; 2017 Feb; 97(2):173-181. PubMed ID: 27671426
[TBL] [Abstract][Full Text] [Related]
19. Teratogenicity of systemic isotretinoin.
Holst H; Muhari-Stark E; Lava SA
Minerva Pediatr; 2018 Feb; 70(1):107-109. PubMed ID: 29363297
[No Abstract] [Full Text] [Related]
20. Teratogenicity from drugs--an increasing problem.
Shepard TH
Dis Mon; 1974 Jun; ():1-32. PubMed ID: 4494537
[No Abstract] [Full Text] [Related]
[Next] [New Search]
